Next generation lipid lowering drugs, resebidrag, Tyskland
| Reference number | |
| Coordinator | LIPIGON PHARMACEUTICALS AB |
| Funding from Vinnova | SEK 15 000 |
| Project duration | November 2017 - February 2018 |
| Status | Completed |
| Venture | Travel grant |
| Call | Travel grant for building international consortia |
Important results from the project
The purpose was to investigate the potential to prepare a Eurostars application between Lipigon, Secarna and Hamburg university. A decision was made to go ahead with the application having Secarna and Lipigon as participants. Secarna will head the application.
Expected long term effects
A positive Eurostars application will render an antisense oligonucleotide drug discovery project, for treatment of dyslipidemia, utilizing the technological expertise of Secarna and the biology knowledge of Lipigon.
Approach and implementation
Lipigon visited the two potential partners in Germany and the proposed project was evaluated based on commercial and scientific viability. It was determined that Hamburg University will be a partner that the consortium buys services from to avoid potential IP issues.